Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With

COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims

Database

Mohamed Hussein, PhD; Wenhui Wei, PhD; Vera Mastey, MS; Robert J. Sanchez, PhD; Degang

Wang, PhD; Dana J. Murdock, MPH, PhD; Boaz Hirshberg, MD; David M. Weinreich, MD;

Jessica J. Jalbert, PhD

Author affiliations: Regeneron Pharmaceuticals, Inc., Tarrytown, New York (Hussein, Wei,

Mastey, Sanchez, Wang, Murdock, Hirshberg, Weinreich, Jalbert)

Corresponding author:

Mohamed Hussein, PhD; Email: mohamed.hussein@regeneron.com

ABSTRACT

Importance: Data on real-world effectiveness of casirivimab and imdevimab (CAS+IMD) for

treatment of coronavirus 2019 (COVID-19) are limited, especially with regard to variants of

concern such as Delta.

Objective: To assess effectiveness of CAS+IMD versus no COVID-19 antibody treatment

among patients diagnosed with COVID-19 in the ambulatory setting overall and among

subgroups, including patients diagnosed during the Delta-dominant period prior to Omicron

emergence.

Design: Retrospective cohort study.

Setting: Komodo Health closed claims database.

Participants: Patients diagnosed with COVID-19 in ambulatory settings from December 2020

through September 2021 treated with CAS+IMD or untreated but treatment-eligible under the

Emergency Use Authorization (EUA). Each treated patient was exact- and propensity score-

matched without replacement to up to 5 untreated EUA-eligible patients.

Exposure: CAS+IMD treatment.

Main Outcomes and Measures: Composite endpoint of 30-day all-cause mortality or COVID-

19-related hospitalization. Kaplan-Meier estimators were used to calculate risk of outcome

overall and across subgroups defined by age groups, COVID-19 vaccination status,

immunocompromised, and timing of COVID-19 diagnosis (December 2020 to June 2021, and

July 2021 to September 2021). Cox proportional-hazards models were used to estimate adjusted

hazard ratios (aHR) and 95% confidence intervals (95% CI).

Results: Among 75 159 patients treated with CAS+IMD and 1 670 338 EUA-eligible untreated

patients, 73 759 treated patients were matched to 310 688 untreated patients; matched patients

2

had an average age ~50 years, approximately 60% were women and were generally well-balanced across risk factors. The 30-day risk of the composite outcome was 2.1% and 5.2% in the CAS+IMD -treated and untreated patients, respectively; CAS+IMD treatment was associated with a 60% lower risk of the outcome (aHR 0.40; 95% CI, 0.38-0.42). The effect of CAS+IMD treatment was consistent across subgroups, including those who received a COVID-19 vaccine (aHR 0.48, 95% CI, 0.41-0.56), and those diagnosed during the Delta-dominant period (aHR 0.40, 95% CI, 0.38-0.42).

Conclusions and Relevance: The real-world effectiveness of CAS+IMD is consistent with the efficacy for reducing all-cause mortality or COVID-19-related hospitalization reported in clinical trials. Effectiveness is maintained across patient subgroups, including those who may be prone to breakthrough infections, and was effective against susceptible variants including Delta. □

INTRODUCTION

Clinical studies have identified neutralizing monoclonal antibodies (mAbs) as efficacious agents of passive immunotherapy for early treatment of patients diagnosed with COVID-19 in the ambulatory setting. ¹⁻⁴ These mAbs, which include casirivimab and imdevimab (CAS+IMD; Regeneron, Inc.), bamlanivimab with etesevimab (Eli Lilly), and sotrovimab (GlaxoSmithKline), have received Emergency Use Authorization (EUA) from the US Food and Drug Administration for treatment of non-hospitalized patients ≥12 years old who have mild-to-moderate COVID-19 and are at high risk of progressing to severe disease, including hospitalization or death. ⁵⁻⁷

While mAbs demonstrated efficacy in COVID-19 patients, emergence of additional variants of concern (VOC) after the completion of clinical trials highlights the need for continued evaluation of mAbs in the real world. Delta (B.1.617.2) and Delta plus (AY.4.2) are VOC that are associated with higher infection rates^{8,9} and increased hospitalization and mortality. ¹⁰⁻¹² *In vitro* studies suggested that CAS+IMD retains neutralization activity against most VOC including Delta but with the exception of Omicron (B.1.1.529). ^{5,13-17} Most real-world studies assessing the effectiveness of CAS+IMD for treating COVID-19¹⁸⁻³⁰ were conducted prior to Delta, and those that did overlap with the emergence of the Delta variant were single-center and of small sample size. ^{19,30,31} Furthermore, with the introduction of COVID-19 vaccines, an improved understanding of vulnerable groups, and the emergence of the Delta variant, it became important to evaluate the effectiveness of CAS+IMD across these patient subgroups. Therefore, the objective of this study was to assess the effectiveness of CAS+IMD compared to no COVID-19 antibody treatment on 30-day all-cause mortality or COVID-19-related hospitalization among patients diagnosed with COVID-19 in the ambulatory setting overall and among patient

subgroups, including among patients diagnosed with COVID-19 during the Delta-dominant period.

METHODS

Study design and patient population

Based on a protocol in which we prespecified our analysis, we conducted a retrospective cohort study using the closed administrative claims data from the Komodo Health claims database; the closed claims dataset contains complete medical and prescription claims information. As of September 30, 2021, approximately 98 000 patients in the dataset who had a COVID-19 diagnosis (ICD-10-CM code U07.1) received intravenous or subcutaneous CAS+IMD. Since all data are de-identified and fully compliant with HIPAA, institutional review board/ethics committee approval was not required for this study.

Among patients diagnosed with COVID-19 in the outpatient setting between December 1, 2020, and September 30, 2021, we identified patients treated with CAS+IMD and patients who were eligible to be treated with CAS+IMD under the EUA but were untreated. Among treated patients, the index date was the date of CAS+IMD administration. For untreated patients, the index date was an assigned date matching the distribution of days from COVID-19 diagnosis to treatment for the CAS+IMD-treated patients. Additional inclusion criteria were continuous enrollment for \geq 6 months pre-index (ie, baseline); age \geq 12 years at index; a COVID-19 diagnosis within 10 days prior to (days 0 to -10) or on the index (day 0) but no diagnosis in the prior 30-day period (days -11 to -40); and a valid date of death. Patients were excluded if

they were treated with other COVID-19 mAbs over the baseline period or on the index date or received CAS+IMD during baseline.

Outcomes

The study outcome was the composite of 30-day all-cause mortality or COVID-19-related hospitalization. Sources used by Komodo to identify mortality included Social Security Administration (SSA) data, a private obituary data source, and a private claims mortality dataset. COVID-19-related-hospitalization was defined as a COVID-19 diagnosis as the primary or admitting diagnosis. Patients were followed from the index date until the occurrence of the outcome or a censoring event, which included receipt of another COVID-19 mAb, the end of 30-day risk period, healthcare plan disenrollment, or study end date (September 30, 2021).

Study variables

Baseline demographic variables included age (as a continuous variable and categorized as 12-17, 18-54, 55-64, \geq 65 years), sex, and geographic region. COVID-19-related variables included location of diagnosis (emergency room/urgent care vs other), the number of days from diagnosis to index date, the index month, and vaccinated against COVID-19 (ie, receipt \geq 1 dose). The Charlson Comorbidity Index (CCI) score was derived using the presence of comorbidities over the baseline period. Body mass index (BMI) was categorized as normal, overweight, and obese based on ICD-10-CM diagnosis codes over the baseline period (including index date). The occurrence of \geq 1 all-cause hospitalization and \geq 1 all-cause emergency room/urgent care visit during the baseline period was also captured. Specific risk factors for use of CAS+IMD under the EUA were identified during the baseline period. These risk factors included age \geq 65 years on

index date; age 12-17 years on index date with BMI≥85th percentile for age and sex based on CDC growth charts³³; BMI>25 kg/m²; pregnancy; diabetes; chronic lung disease; immunosuppressive disease; history of immunosuppressive treatment; cardiovascular disease, hypertension, or congenital heart disease; sickle cell disease; and neurodevelopmental disorders. The following EUA risk factors were evaluated over the baseline period only and did not include the index date since COVID-19 could result in these conditions: chronic kidney disease, cardiovascular disease or hypertension, and use of medical-related technological dependence.

Subgroups

Subgroups of interest included age groups of 12-17, 18-54, 55-64, and ≥65 years; elevated risk defined as age ≥65 years or 55-64 years with BMI ≥35 kg/m², type 2 diabetes, chronic obstructive pulmonary disease, or chronic kidney disease; immunocompromised, ie, B-cell deficiencies, both overall and by type of deficiency (primary, secondary, and drug-induced as defined in Supplementary Table 1; vaccinated against COVID-19; and timing of COVID-19 diagnosis (December 2020 to June 2021 vs July 2021 onward, which is the month the Delta variant became the dominant variant in the US).³⁴ A post-hoc analysis was also conducted among vaccinated patients who were also at elevated risk based on the above definition.

Statistical analysis

Matching

Propensity scores (PS), derived using logistic regression, predicted the probability of CAS+IMD treatment vs no treatment given age, sex, index month, 3-digit zip code, days between COVID-19 diagnosis and index date, individual EUA criteria, BMI category, CCI score, COVID-19

vaccination status, and baseline health care resource utilization. CAS+IMD -treated patients were then matched using a caliper of 0.2 of the standard deviation of the logit of the estimated PS³⁵ and exact matched to up to 5 untreated EUA-eligible patients without replacement on the index month, 3-digit zip code, and days from COVID-19 diagnosis to index date. Missing data were accounted for by including an indicator variable. Balance between groups was measured by standardized mean differences (SMD) with value \geq 0.1 indicating imbalance.³⁶

Primary analysis

Baseline characteristics including means, standard deviations, medians, and interquartile ranges (IQR) for continuous variables, and frequency and percent for categorical variables are reported among treated and untreated matched patients. Kaplan-Meier estimators were used to estimate the 30-day risk of the composite outcome among the matched patients, 37 with 95% confidence bands across the entire KM survival curves constructed using the Hall-Wellner method. Log-ranks tests were used to compare survival distributions.

Adjusted hazard ratios (aHR) with 95% confidence intervals (CI) were derived using Cox proportional-hazards models that fit the model to the matched pairs, and used sandwich variance estimators to account for clustering within matched sets.³⁹

Subgroup analyses

The 30-day outcome risk for each subgroup was derived using KM estimators. Cox proportional-hazards models were used to estimate the effectiveness of CAS+IMD across subgroups using interaction terms between treatment and the subgroup in the model; results are presented as the

8

aHR with its 95% CI. These estimates were derived from the same matched set of patients as the primary analysis and accounted for clustering of patients without adjustment for multiplicity of testing.

Sensitivity analyses

Sensitivity analyses included modifying the definition of COVID-19-related hospitalization to having a COVID-19 diagnosis in the primary position, requiring that only the untreated patients meet EUA criteria, shortening the time window between diagnosis and treatment to 5 days from 10 days, and using 3 months pre-index continuous enrollment instead of 6 months.

The analytic file was created and all analyses were conducted using SAS software (version 9.4, SAS Institute Inc., Cary, NC).

RESULTS

Patient populations

Among 13 273 128 patients who had a COVID-19 diagnosis during the study period in the closed claims Komodo dataset, 75 159 patients who received CAS+IMD and 1 670 338 untreated patients met study criteria and were eligible for matching. Prior to matching, the groups were imbalanced on several variables (Supplementary Table 2).

Among treated patients, 73 759 were successfully matched to 310 688 patients who were EUA-eligible but untreated (Supplementary Figure 1). After matching, the SMDs indicated no imbalance between treated and matched EUA-eligible untreated patients on any of the baseline

9

variables (Table 1). Treated and EUA-eligible untreated patients were primarily female (~60%), with a mean age ~50 years, with greatest representation from the South (65-67%). The mean (SD) and median (IQR) number of days from diagnosis to index date in the CAS+IMD-treated cohort were 1.6 (2.1) and 1 (3) days, respectively, and the timing was comparable for the assigned index dates for the EUA-eligible untreated patients. Among the individual EUA criteria, the combination of cardiovascular disease, hypertension, and congenital heart disease had the highest prevalence (53-55%) followed by neurodevelopmental disorders (~37%) and being overweight (34-36%) (Table 1).

Primary analysis

The 30-day risk of all-cause mortality or COVID-19-related hospitalizations was 2.1% (95% CI, 2.0-2.2) in the CAS+IMD -treated cohort and 5.2% (95% CI, 5.1-5.3) in the EUA-eligible untreated cohort (Figure 1) representing 1486 and 15 027 events, respectively. Most of the events in both cohorts occurred within the first 10 days post-index. In adjusted models, CAS+IMD was associated with a 60% lower risk of the composite outcome compared to the untreated EUA eligible patients (aHR 0.40; 95% CI, 0.38-0.42) (Figure 2). The number of deaths observed during the 30-day post-index period was lower in the treated cohort relative to those who did not receive treatment, 51 and 1491, respectively, and the 30-day mortality risk was 0.1% (95% CI 0.06% to 0.11%) in the treated cohort and 0.6% (95% CI 0.56% to 0.62%) in the untreated cohort, respectively. Multiple sensitivity analyses showed results that were consistent with the primary analysis (Figure 2)

Subgroup analyses

The 30-day outcome risk among untreated EUA-eligible patients was highest for patients in the oldest age groups, and among those at elevated risk or who are immunocompromised (B-cell deficient) (Figure 4). After matching, the effectiveness of treatment with CAS+IMD was consistent across patient subgroups defined by age, COVID-19 vaccination status, elevated risk, and immunocompromised (Figure 4); there was a greater risk reduction among those with primary or secondary B-cell deficiency, although the numbers are small. Post-hoc analysis also showed that the treatment was associated with a 60% reduction in risk among vaccinated patients who were also at elevated risk (aHR 0.40; 95% CI 0.28–0.57).

Regardless of whether they were treated during the Delta-dominant period or not, patients who received CAS+IMD had a lower risk than EUA-eligible non-treated patients (Figure 3).

Treatment with CAS+IMD was associated with a 50% lower risk (aHR 0.50; 95% CI, 0.43-0.58) during the earlier period, and a 60% lower risk (aHR 0.40; 95% CI, 0.38-0.42) during Delta-dominant period (Figure 4).

DISCUSSION

This observational cohort study confirms and extends the evidence from clinical trials and other smaller real-world studies that patients with COVID-19 in the outpatient setting benefit from treatment with CAS+IMD. Among patients treated with CAS+IMD, there was a 60% reduction in the risk of 30-day all-cause mortality or COVID-19-related hospitalization compared to the EUA-eligible untreated patients. The benefit of treatment was observed across all patient subgroups. Notably, we found that the effectiveness of CAS+IMD was maintained during the Delta-dominant period and among patients receiving ≥1 dose of the COVID-19 vaccine.

In the primary analysis, the 60% reduction in risk is within the range of 50-90% lower risk of hospitalizations relative to untreated patients that was suggested by published real-world studies, ^{18,19,22,40,41} although most of those studies used more broadly defined endpoints such as all-cause hospitalizations. ^{18,40,41} Moreover, the risk reduction observed in this study is comparable to the 60% risk reduction of the same composite endpoint that was observed with CAS+IMD treatment compared to untreated EUA-eligible patients in a real-world study based on data from 2 large claims databases in the pre-Delta period. ⁴² Our results are also consistent with those of the clinical trial demonstrating the efficacy of CAS+IMD for the treatment of COVID-19² and suggest the benefits of CAS+IMD extend beyond the clinical trial setting. The subgroup analyses demonstrate that CAS+IMD is effective regardless of age or COVID-19 vaccination status, and is also effective in high-risk patient populations including those who are immunocompromised.

An important finding of this study was that the effectiveness of CAS+IMD was maintained when Delta was the dominant SARS-CoV-2 variant in the US. The Delta variant was of special concern because of its greater virulence in addition to its high transmissibility, which quickly made it the predominant variant. ⁸⁻¹² In the adjusted model, the aHRs showed that the magnitude of the treatment effect was slightly higher during the Delta-dominant period than the pre-Delta period (60% and 50% lower risk, respectively, relative to EUA-eligible untreated patients). While the observed difference may have been driven by lower accessibility and stricter patient selection in the pre-Delta period, our results demonstrate that CAS+IMD retains activity against the Delta variant. Such activity was previously suggested by *in vitro* studies ^{5,13-16} and

smaller real-world studies that reported its effectiveness for reducing all-cause hospitalization or mortality.^{30,31}

An additional consequence of the emergence of variants such as Delta that are characterized by increased virulence is the occurrence of breakthrough infections among vaccinated individuals. 43-45 Limited evidence has suggested that breakthrough infections in fully vaccinated patients are amenable to treatment with CAS+IMD. 19,31 In the current analysis, the 52% reduction in risk among vaccinated patients suggests patients vaccinated against COVID-19 who experience breakthrough infections due to waning immunity or lack of effectiveness of vaccines can benefit from treatment. 19 In addition, the reduction in outcome risk among patients treated with CAS+IMD was slightly greater (61%) among unvaccinated than vaccinated patients, likely resulting from a greater risk of severe COVID-19 among those who are not vaccinated. While these results support the benefits of treatment among those who cannot be or are unwilling to be vaccinated, they also suggest vaccinated individuals who contract COVID-19 and are eligible for treatment under the EUA can also benefit from treatment with CAS+IMD.

The findings of this study also suggest that immunocompromised patients (ie, B-cell deficient) can benefit from treatment with CAS+IMD. This is relevant because these patients have been shown to be at higher risk of being infected with COVID-19 and of progressing to more severe disease with poorer outcomes. Furthermore, patients with primary immunodeficiencies have a low likelihood of benefitting from vaccination, which makes them a group with a large unmet need.

Limitations

Limitations of this study include that information on viral load and symptoms, variables that may predict severe COVID-19, 49-51 are not captured in claims data. Moreover, a reason that at least some EUA-eligible patients were untreated may be that they had less severe disease, although social and cultural factors have also been reported to play a role in the decision for treatment with mAbs.⁵² If untreated patients had less severe disease than treated patients, the residual confounding would likely bias results against CAS+IMD. Another limitation is that several important variables such as BMI and COVID-19 vaccination status are not well captured in claims data; when this study was conducted, approximately 70% of the population had received 1 dose and 60% had received 2 doses. Residual confounding is likely, and if unvaccinated patients with higher BMIs are likely to have worse disease requiring treatment, it could result in underestimation of the effectiveness of CAS+IMD. We were also not able to distinguish between the subcutaneous and intravenous administration of CAS+IMD. Finally, the study period did not overlap with emergence of the Omicron variant, although CAS+IMD is not expected to be active against Omicron,⁵³ as in vitro data indicate CAS+IMD has markedly reduced neutralization activity against this variant. 54,55

CONCLUSIONS

This study suggests that, in susceptible variants, treatment with CAS+IMD is effective against COVID-19 and its effectiveness is maintained across various patient subgroups. Among patients diagnosed with COVID-19 in the ambulatory setting, treatment with CAS+IMD was associated with a 60% reduction in risk of 30-day all-cause mortality or COVID-19-related hospitalization relative to matched untreated EUA-eligible patients that was maintained even after the

emergence of the Delta variant and across a number of high-risk patient populations. While

breakthrough infections are likely, especially in patients with risk factors and after emergence of

VOC with reduced sensitivity to vaccines or with waning immunity, early treatment of these

patients with CAS+IMD reduced the risk of disease progression that would require

hospitalization or result in death. Evaluation of COVID-19 treatments and outcomes needs to

remain ongoing as new VOC emerge so risk factors that can further improve COVID-19

management strategies can be identified.

ACKNOWLEDGEMENTS

Author Contributions: All authors had full access to all of the data in the study and take

responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Mohamed Hussein, Wenhui Wei, Vera Mastey, Robert J. Sanchez, Dana

Murdock, David M. Weinreich, Jessica J. Jalbert

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Mohamed Hussein, Wenhui Wei, Jessica J. Jalbert

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Degang Wang, Wenhui Wei

Administrative, technical, or material support: Degang Wang

Conflict of Interest Disclosure: All authors are employees and stockholders of Regeneron

Pharmaceuticals, Inc.

Funding/Support: Regeneron Pharmaceuticals, Inc.

Role of the Funder/Sponsor: Regeneron Pharmaceuticals Inc was involved in the design

15

and conduct of the study.

Data Sharing: All data generated or analysed during this study are included in this published article.

Additional Contributions: Medical writing support was provided by E. Jay Bienen, PhD, and was funded by Regeneron Pharmaceuticals, Inc. Data programming and analytics support was provided by Wenqin Qiang and Dehua Kan from KMK Consulting Inc. and was funded by Regeneron Pharmaceuticals, Inc.

REFERENCES

- 1. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N Engl J Med*. Dec 17 2020;384(3):238-251. doi:10.1056/NEJMoa2035002
- 2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. *N Engl J Med*. Sep 29 2021;385:e81. doi:10.1056/NEJMoa2108163
- 3. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. *JAMA*. 2021;325(7):632-644. doi:10.1001/jama.2021.0202
- 4. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *N Engl J Med*. Nov 18 2021;385(21):1941-1950. doi:10.1056/NEJMoa2107934
- 5. U.S. Food & Drug Administration. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. Revised January 2022. Accessed March 6, 2022. https://www.fda.gov/media/145611/download
- 6. U.S. Food & Drug Administration. Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. Revised December 2021. Accessed January 21, 2022. https://www.fda.gov/media/145802/download
- 7. U.S. Food & Drug Administration. Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of Sotrovimab. Revised November 2021. Accessed January 21, 2022. https://www.fda.gov/media/149534/download

- 8. Allen H, Vusirikala A, Flannagan J, et al. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study. *Lancet Reg Health Eur.* Jan 2022;12:100252. doi:10.1016/j.lanepe.2021.100252
- 9. Luo CH, Morris CP, Sachithanandham J, et al. Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the Alpha Variant in both unvaccinated and vaccinated individuals. *Clin Infect Dis.* 2021:Dec 18: (Online ahead of print) doi: 10.1093/cid/ciab986. . doi:10.1093/cid/ciab986.
- 10. Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the USA. *Lancet Infect Dis*. Dec 2021;21(12):1629-1630. doi:10.1016/S1473-3099(21)00685-X
- 11. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. *CMAJ*. Oct 25 2021;193(42):E1619-E1625. doi:10.1503/cmaj.211248
- 12. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis.* 2022;22(1):35-42. doi:10.1016/S1473-3099(21)00475-8
- 13. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature*. May 2021;593(7857):130-135. doi:10.1038/s41586-021-03398-2
- 14. Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. *Cell.* Jul 22 2021;184(15):3949-3961 e11. doi:10.1016/j.cell.2021.06.002

- 15. Wilhelm A, Toptan T, Pallas C, et al. Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q. *Viruses*. Aug 26 2021;13(9)doi:10.3390/v13091693
- 16. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*. Aug 2021;596(7871):276-280. doi:10.1038/s41586-021-03777-9
- 17. Syed AM, Ciling A, Khalid MM, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. *medRxiv*. 2022:2021.12.20.21268048. doi:10.1101/2021.12.20.21268048
- 18. Cooper MH, Christensen PA, Salazar E, et al. Real-world assessment of 2,879 COVID-19 patients treated with monoclonal antibody therapy: a propensity score-matched cohort study. *Open Forum Infect Dis.* 2021;8(11):ofab512. doi:10.1093/ofid/ofab512
- 19. Bierle DM, Ganesh R, Tulledge-Scheitel S, et al. Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities. *J Infect Dis.* 2022;225(4):598-602. doi:10.1093/infdis/jiab570
- 20. Ganesh R, Philpot LM, Bierle DM, et al. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. *J Infect Dis.* Jul 19 2021;224(8):1278-1286. doi:10.1093/infdis/jiab377
- 21. Razonable RR, Aloia NCE, Anderson RJ, et al. A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate Coronavirus Disease-19: the Mayo Clinic model. *Mayo Clin Proc.* 2021;96(5):1250-1261. doi:10.1016/j.mayocp.2021.03.010

- 22. Verderese JP, Stepanova M, Lam B, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19: a real-world experience. *Clin Infect Dis.* Jun 24 2021:Jun 24 [Online ahead of print] doi: 10.1093/cid/ciab579. doi:10.1093/cid/ciab579
- 23. Webb BJ, Buckel W, Vento T, et al. Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19. *Open Forum Infect Dis*. 2021;8(7)doi:10.1093/ofid/ofab331
- 24. Chilimuri S, Mantri N, Gurjar H, et al. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience. *J Natl Med Assoc*. 2021;113(6):701-705. doi:10.1016/j.jnma.2021.08.036
- 25. Close RM, Jones TS, Jentoft C, McAuley JB. Outcome comparison of high-risk Native American patients who did or did not receive monoclonal antibody treatment for COVID-19. *JAMA Netw Open.* 2021;4(9):e2125866-e2125866. doi:10.1001/jamanetworkopen.2021.25866
- 26. Kakinoki Y, Yamada K, Tanino Y, et al. Impact of antibody cocktail therapy combined with casirivimab and imdevimab on clinical outcome for Covid-19 patients in a real-life setting: a single institute analysis. *Int J Infect Dis.* 2022;117:189-194. doi:10.1101/2021.10.10.21264589
- 27. Piccicacco N, Zeitler K, Montero J, et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 monoclonal antibody infusions in high-risk outpatients. *Open Forum Infect Dis.* 2021;8(7)doi:10.1093/ofid/ofab292
- 28. Falcone M, Tiseo G, Valoriani B, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. *Infect Dis Ther*. 2021/12/01 2021;10(4):2479-2488. doi:10.1007/s40121-021-00525-4

- 29. Anderson B, Smith Z, Edupuganti S, Yan X, Masi CM, Wu HM. Effect of monoclonal antibody treatment on clinical outcomes in ambulatory patients with coronavirus disease 2019. *Open Forum Infect Dis.* 2021;8(7)doi:10.1093/ofid/ofab315
- 30. McCreary EK, Bariola JR, Wadas RJ, et al. Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19. *medRxiv*. 2021:Dec 1 [preprint] doi: 10.1101/2021.11.30.21266756. doi:10.1101/2021.11.30.21266756
- 31. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. *J Clin Virol*. Dec 2021;145:105026. doi:10.1016/j.jcv.2021.105026
- 32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383.
- 33. Centers for Disease Control and Prevention. Clinical Growth Charts. Accessed November 23, 2021. https://www.cdc.gov/growthcharts/clinical_charts.htm
- 34. Wadman M. What does the Delta variant have in store for the United States? We asked coronavirus experts. ScienceInsider. August 4, 2021. Accessed March 6, 2022. https://www.science.org/content/article/what-does-delta-variant-have-store-us-we-asked-coronavirus-experts
- 35. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm Stat.* MarApr 2011;10(2):150-61. doi:10.1002/pst.433

- 36. Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. *J Clin Epidemiol*. Aug 2013;66(8 Suppl):S84-S90 e1. doi:10.1016/j.jclinepi.2013.01.013
- 37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc.* 1958;53:457-481.
- 38. Hall WJ, Wellner JA. Confidence bands for a survival curve from censored data. *Biometrika*. 1980;67:133-143.
- 39. Lin DY, Wei LJ. The robust inference for the Cox Proportional Hazards Model. *J Am Stat Assoc.* 1989/12/01 1989;84(408):1074-1078. doi:10.1080/01621459.1989.10478874
- 40. Razonable RR, Pawlowski C, O'Horo JC, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. *EClinicalMedicine*. 2021;40:101102. doi:10.1016/j.eclinm.2021.101102
- 41. Webb BJ, Buckel W, Vento T, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. *Open forum infectious diseases*. 2021;8(7):ofab331. doi:10.1093/ofid/ofab331
- 42. Wei W, Murdock D, Sanchez RJ, et al. Real-world effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting: An analysis of two large US National Claims databases. [Data on file; manuscript submitted to *Clin Infect Dis*].
- 43. Kislaya I, Rodrigues EF, Borges V, et al. Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with Delta and Alpha variants. *Emerg Infect Dis*. Dec 8 2021;28(2)doi:10.3201/eid2802.211789

- 44. Christensen PA, Olsen RJ, Long SW, et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. *Am J Pathol*. 2022;192(2):320-331. doi:10.1016/j.ajpath.2021.10.019
- 45. Marques AD, Sherrill-Mix S, Everett J, et al. SARS-CoV-2 variants associated with vaccine breakthrough in the Delaware Valley through summer 2021. *mBio*. 2022:Feb 8 (Online ahead of print) doi: 10.1128/mbio.03788-21. doi:10.1128/mbio.03788-21
- 46. Shields AM, Burns SO, Savic S, Richter AG, Consortium UPC-. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. *J Allergy Clin Immunol*. Mar 2021;147(3):870-875 e1. doi:10.1016/j.jaci.2020.12.620
- 47. Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing B Cell depletion therapy and those with humoral immunodeficiency states: a scoping review. *Pathog Immun*. 2021;6(1):76-103. doi:10.20411/pai.v6i1.435
- 48. Pham MN, Murugesan K, Banaei N, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. *J Allergy Clin Immunol*. Mar 2022;149(3):907-911 e3. doi:10.1016/j.jaci.2021.11.022
- 49. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun*. 2020/10/30 2020;11(1):5493. doi:10.1038/s41467-020-19057-5
- 50. Trunfio M, Venuti F, Alladio F, et al. Diagnostic SARS-CoV-2 cycle threshold value predicts disease SEVERITy, survival, and six-month sequelae in COVID-19 symptomatic patients. *Viruses*. Feb 11 2021;13(2)doi:10.3390/v13020281
- 51. Boyapati A, Wipperman MF, Ehmann PJ, et al. Baseline severe acute respiratory syndrome viral load is associated with coronavirus disease 2019 severity and clinical outcomes:

post hoc analyses of a phase 2/3 trial. *J Infect Dis*. Dec 1 2021;224(11):1830-1838. doi:10.1093/infdis/jiab445

- 52. Bierle DM, Ganesh R, Wilker CG, et al. Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19. *J Prim Care Community Health*. Jan-Dec 2021;12:21501327211019282. doi:10.1177/21501327211019282
- 53. Cavazzoni P. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant. Accessed February 1, 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron
- 54. Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. *medRxiv*. 2021:Dec 8 [Preprint] doi.org/10.1101/2021.12.07.21267432.
- 55. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. *Nature*. 2022;602(7898):671-675.

Figure 1. Kaplan-Meier Curve for 30-Day All-Cause Mortality or COVID-19-Related

Hospitalization Among Patients Diagnosed With COVID-19 in the Outpatient Setting Who

Were Treated With CAS+IMD or Who Were EUA-Eligible But Untreated

Figure 2. Primary and Sensitivity Analyses of 30-Day All-Cause Mortality or COVID-19-

Related Hospitalization Among Patients Diagnosed With COVID-19 in the Outpatient

Setting

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval.

Figure 3. Kaplan-Meier Curve for Composite Endpoint of 30-day All-Cause mortality or

COVID-19-Related Hospitalization Among Patients Diagnosed With COVID-19 in the

Outpatient Setting, Stratified by Treatment Received and Timing of COVID-19 Diagnosis

Figure 4. Subgroup Analyses of 30-Day Risk of All-Cause Mortality or COVID-19-Related

Hospitalization Among Patients Diagnosed With COVID-19 in the Outpatient Setting

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval.

^a Defined as age ≥65 years or 55-64 years with BMI ≥35 kg/m², type 2 diabetes, chronic

25

obstructive pulmonary disease, or chronic kidney disease.

Table 1. Baseline Characteristics of the Matched Cohorts

Variable	CAS+IMD	EUA-eligible	SMD ^a
	(n = 73759)	untreated	
		(n = 310 688)	
Age, years			
Mean \pm SD (range)	49.8 ±15.5	50.0 ± 16.6	0.01
Median (IQR)	51 (22)	51 (23)	_
Range	12-89	12-89	_
Age group, years, n (%)			
12-17	1651 (2.2)	8515 (2.7)	0.03
18-34	11 395 (15.5)	50 994 (16.4)	0.03
35-44	13 656 (18.5)	56 873 (18.3)	0.01
45-54	16 036 (21.7)	64 951 (20.9)	0.02
55-64	19 245 (26.1)	73 742 (23.7)	0.06
65-74	8156 (11.1)	33 339 (10.7)	0.01
75-84	2829 (3.8)	15 727 (5.1)	0.06
≥85	791 (1.1)	6547 (2.1)	0.08
Sex, n (%)			
Female	43 989 (59.6)	187 438 (60.3)	0.01
Male	29 770 (40.4)	123 250 (39.7)	0.01
Region, n (%)			
Midwest	11 969 (16.2)	51 787 (16.7)	0.01
Northeast	6914 (9.4)	32 968 (10.6)	0.04

Variable	CAS+IMD	EUA-eligible	SMD ^a	
	(n = 73759)	untreated		
		(n = 310 688)		
South	49 744 (67.4)	203 380 (65.5)	0.04	
West	5132 (7.0)	22 553 (7.3)	0.01	
BMI category, n (%) ^b				
Not overweight	2103 (2.9)	9242 (3.0)	0.01	
Overweight (25-<30 kg/m ²)	5991 (8.1)	26 110 (8.4)	0.01	
Obese (30-<35 kg/m ²)	6829 (9.3)	28 835 (9.3)	0.00	
Severely obese (35-<40 kg/m ²)	5721 (7.8)	22 672 (7.3)	0.02	
Morbidly obese (≥40 kg/m²)	7851 (10.6)	28 854 (9.3)	0.05	
Missing	45 264 (61.4)	194 975 (62.8)	0.03	
CCI score, mean \pm SD	1.18 ± 1.74	1.11 ± 1.74	0.04	
Hospitalization during baseline	10 154 (13.8)	41 451 (13.3)		
period, n (%)			0.01	
Month of index date, n (%)				
December 2020	668 (0.9)	3258 (1.1)	0.02	
January 2021	1910 (2.6)	9303 (3.0)	0.03	
February 2021	984 (1.3)	4538 (1.5)	0.01	
March 2021	1015 (1.4)	4697 (1.5)	0.01	
April 2021	1345 (1.8)	6067 (2.0)	0.01	
May 2021	720 (1.0)	2989 (1.0)	0.00	
June 2021	474 (0.6)	1823 (0.6)	0.01	

Variable	CAS+IMD	EUA-eligible	SMD ^a	
	(n = 73759)	untreated		
		(n = 310 688)		
July 2021	6374 (8.6)	27 698 (8.9)	0.01	
August 2021	31 190 (42.3)	132 837 (42.8)	0.01	
September 2021	29 079 (39.4)	117 478 (37.8)	0.03	
Time from diagnosis to index date,				
days				
$Mean \pm SD$	1.6 ± 2.1	1.5 ± 2.1	0.03	
Median (IQR)	1 (3)	1 (3)		
Range	0-10	0-10		
Time from diagnosis to index date,				
days, n (%)				
0	33 694 (45.7)	149 534 (48.1)	0.05	
1	12 442 (16.9)	49 223 (15.8)	0.03	
2	8768 (11.9)	34 176 (11.0)	0.03	
≥3	18 855 (25.6)	77 755 (25.0)	0.01	
Initial outpatient COVID-19	22 075 (29.9)	83 191 (26.8)		
diagnosis in ER, n (%)			0.07	
Vaccinated	12 983 (17.6)	52 681 (17.0)	0.02	
EUA criteria				
Age ≥65 years	11 776 (16.0)	55 613 (17.9)	0.05	
Children overweight ^c	607 (0.8)	2199 (0.7)	0.01	

ariable	CAS+IMD	EUA-eligible	SMD ^a	
	(n = 73759)	untreated		
		(n = 310 688)		
Overweight	26 392 (35.8)	106 471 (34.3)	0.03	
Pregnancy	2653 (3.6)	12 322 (4.0)	0.02	
Chronic kidney disease	3003 (4.1)	12 237 (3.9)	0.01	
Diabetes	19 259 (26.1)	74 881 (24.1)	0.05	
Chronic pulmonary disease	15 904 (21.6)	63 419 (20.4)	0.03	
Immunosuppressive disease	8321 (11.3)	31 189 (10.0)	0.04	
Immunosuppressant use	3428 (4.7)	10 303 (3.3)	0.07	
Sickle cell disease	211 (0.3)	913 (0.3)	0.00	
Cardiovascular disease,	40 316 (54.7)	163 107 (52.5)		
hypertension, or congenital heart				
disease			0.04	
Neurodevelopmental disorders	27 579 (37.4)	114 661 (36.9)	0.01	
Medical-related technological	18 840 (25.5)	75 496 (24.3)		
dependence			0.03	
B-cell deficiency	4483 (6.1)	14 185 (4.6)	0.07	
Primary	15 (<0.1)	33 (<0.1)	0.01	
Secondary	183 (0.3)	560 (0.12)	0.02	
Drug-induced	4285 (5.8)	13 592 (4.4)	0.07	
Cancer or chemotherapy	8486 (11.5)	29 069 (9.4)	0.07	
Cancer	6199 (8.4)	21 280 (6.9)	0.06	


ariable	CAS+IMD	EUA-eligible	SMD ^a	
	(n = 73759)	untreated		
		(n = 310 688)		
Chemotherapy	3650 (5.0)	11 579 (3.7)	0.06	

Abbreviations: BMI, body mass index; CAS+IMD, casirivimab and imdevimab; CCI, Charlson Comorbidity Index; ER, emergency room; EUA, Emergency Use Authorization; IQR, interquartile range; SD, standard deviation; SMD, standardized mean difference.


^a Value ≥0.1 indicates significant imbalance between cohorts.

^b Based on diagnoses relating to the BMI categories.

^c Based on BMI≥85th percentile for age and sex among those 12-17 years old.



Analysis	CAS+IMD Events/n 30-l	Day Risk(%)	EUA-eligible ui Events/n 30-D		aHR (95% CI)	
Primary Analysis	1486 /73759	(2.1)	15027/310688	(5.2)	0.40 (0.38, 0.42)	H =1
Sensitivity Analysis						
COVID-19 as primary only	1486 /73759	(2.1)	15011/310688	(5.2)	0.40 (0.38, 0.42)	H
Treatment within 5 days of diagnosis	1485 /73734	(2.1)	15906/310231	(5.5)	0.38 (0.36, 0.39)	н
EUA criteria not required for treatment group	1814 /95048	(2.0)	16192/364072	(4.8)	0.41 (0.39, 0.43)	•
3 month continuous insurance coverage at baseline	1549 /76523	(2.1)	15736/323500	(5.2)	0.40 (0.38, 0.42)	H■I 0.3 0.5 1
						Favors Treatment



	CAS+IMD		EUA-eligible			
Analysis	Events/n 30-D	ay Risk(%)	Events/n 30-D	Day Risk(%)	aHR (95% CI)	I
Age group, year						
12-17	4 /1651	(0.3)	60/8515	(8.0)	0.32 (0.13, 0.75)	⊢ •
18-54	674 /41087	(1.7)	6500/172818	(4.0)	0.42 (0.39, 0.46)	=
55-64	454 /19245	(2.5)	4618/73742	(6.7)	0.36 (0.33, 0.39)	 =
≥ 65	354 /11776	(3.2)	3849/55613	(7.6)	0.42 (0.38, 0.47)	l = l
Vaccination status						
Vaccinated	172 /12983	(1.4)	1305/52681	(2.7)	0.48 (0.41, 0.56)	⊢= -
Unvaccinated	1314 /60776	(2.3)	13722/258007	(5.7)	0.39 (0.37, 0.41)	H
Elevated Risk						
Yes	634 /22796	(2.9)	6768/95028	(7.7)	0.37 (0.34, 0.40)	H
No	852 /50963	(1.8)	8259/215660	(4.1)	0.43 (0.40, 0.45)	H
B-cell deficiency						
Yes	146 /4483	(3.5)	972/14185	(7.4)	0.44 (0.37, 0.52)	 ■
No	1340 /69276	(2.0)	14055/296503	(5.1)	0.39 (0.37, 0.42)	H
Types of B-cell deficiency				. ,		
Primary	0 /15	(0.0)	3/33	(9.2)	N/A	
Secondary	2 /183	(1.2)	60/560	(12)	0.12 (0.03, 0.50)	⊢ •
Drug-induced	144 /4285	(3.6)	909/13592	(7.2)	0.46 (0.39, 0.55)	· +=-
No	1340 /69276	(2.0)	14055/296503	(5.1)	0.39 (0.37, 0.42)	H I
Time period of COVID-19 diagnosis		. ,				
December 2020 to June 2021	176 /7116	(2.5)	1610/32675	(5.0)	0.40 (0.38, 0.42)	H
July 2021 to end of study	1310 /66643	(2.1)	13417/278013	(5.2)	0.50 (0.43, 0.58)	
•		. ,		` '	. , ,	
						0.0 0.2 0.4 0.6 0.8 1.0
						← Favors Treatment